Characteristics and outcomes of patients treated with sotrovimab to prevent progression to severe COVID-19 in Belgium

被引:0
作者
Drysdale, Myriam [1 ]
Hautekiet, Thor [2 ]
Singh, Moushmi [1 ]
Hautekiet, Joris [3 ]
Ludikhuyze, Linda [3 ]
Patel, Vishal [1 ]
Gibbons, Daniel C. [1 ]
De Roeck, Dorothee [4 ]
Colpaert, Kirsten [5 ]
Lloyd, Emily J. [1 ]
Van Braeckel, Eva [2 ,6 ]
机构
[1] GSK, Value Evidence & Outcomes, Brentford, England
[2] Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium
[3] IQVIA BeNeLux, Real World Evidence, Zaventem, Belgium
[4] GSK, Med BeNeLux, Wavre, Belgium
[5] Ghent Univ Hosp, Dept Intens Care, Ghent, Belgium
[6] Univ Ghent, Fac Med & Hlth Sci, Dept Internal Med & Pediat, Resp Infect & Def Lab, Ghent, Belgium
关键词
COVID-19; monoclonal antibody; Omicron BA.1; Omicron BA.2; sotrovimab;
D O I
10.1080/17843286.2024.2381272
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Sotrovimab, a dual-action, engineered human monoclonal antibody, has been demonstrated to significantly reduce the risk of hospitalisation and death in high-risk patients with COVID-19. Here, we describe the real-world use of, and outcomes from, sotrovimab treatment in Belgium during the Delta and Omicron waves among patients with COVID-19 at high risk of developing severe disease. Methods This was a multicentric, single-arm observational cohort study of non-hospitalised patients receiving outpatient sotrovimab treatment between 1 November 2021 and 2 August 2022 at nine hospitals in Belgium. The primary outcomes were all-cause and COVID-19-related hospitalisations and all-cause deaths during the 29-day acute follow-up period from first administration of sotrovimab. Results A total of 634 patients were included (63.4% aged < 65 years; 50.3% male). A high proportion (67.7%; n = 429/634) of patients were immunocompromised, with 36.9% (n = 234/634) actively treated for malignancy. During the 29-day acute period, 12.5% (n = 79/634) of sotrovimab-treated patients were hospitalised due to any cause (median duration 4 days; median time to hospitalisation 14 days) and 1.1% (n = 7/634) died due to any cause. The proportion of sotrovimab-treated patients experiencing COVID-19-related hospitalisation was highest during the Delta predominance and Delta/BA.1 codominance (both 6.3%) periods. During the BA.1 predominance, BA.1/BA.2 codominance and BA.2/BA.5 codominance periods, COVID-19-related hospitalisations were consistently low (all <= 2.7%). Conclusion This study indicated low rates of COVID-19-related hospitalisations and all-cause deaths in sotrovimab-treated patients in Belgium, including during Omicron subvariant periods, despite over two-thirds of the study population being immunocompromised.
引用
收藏
页码:174 / 183
页数:10
相关论文
共 50 条
  • [21] Clinical characteristics and prognostic factors of COVID-19 patients progression to severe: a retrospective, observational study
    Liao, Yunfei
    Feng, Yong
    Wang, Bo
    Wang, Hanyu
    Huang, Jinsha
    Wu, Yaxin
    Wu, Ziling
    Chen, Xiao
    Yang, Chao
    Fu, Xinqiao
    Sun, Hui
    [J]. AGING-US, 2020, 12 (19): : 18853 - 18865
  • [22] Mortality and renal outcomes of patients with severe COVID-19 treated in a provisional intensive care unit
    Hittesdorf, Erin
    Panzer, Oliver
    Wang, David
    Stevens, Jacob S.
    Hastie, Jonathan
    Jordan, Desmond A.
    Yoh, Nina
    Eiseman, Katherine A.
    Elisman, Katerina
    Wagener, Gebhard
    [J]. JOURNAL OF CRITICAL CARE, 2021, 62 : 172 - 175
  • [23] Clinical characteristics and outcomes of COVID-19 patients with prediabetes
    Chandrasekaran, Nirmala Devi
    Rao, Mohan Rao Velure Raja
    Sathish, Thirunavukkarasu
    [J]. DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2021, 15 (04)
  • [24] Clinical characteristics and outcomes of cancer patients with COVID-19
    Yang, Fan
    Shi, Shaobo
    Zhu, Jiling
    Shi, Jinzhi
    Dai, Kai
    Chen, Xiaobei
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (10) : 2067 - 2073
  • [25] Clinical characteristics and outcomes of patients with COVID-19 and psoriasis
    Meng, Yu
    Zeng, Furong
    Sun, Huiyan
    Li, Yayun
    Chen, Xiang
    Deng, Guangtong
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (12) : 5850 - 5857
  • [26] Characteristics and outcomes of sepsis patients with and without COVID-19
    Heubner, Lars
    Hattenhauer, Sara
    Gueldner, Andreas
    Petrick, Paul Leon
    Roessler, Martin
    Schmitt, Jochen
    Schneider, Ralph
    Held, Hanns Christoph
    Mehrholz, Jan
    Bodechtel, Ulf
    Ragaller, Maximilian
    Koch, Thea
    Spieth, Peter Markus
    [J]. JOURNAL OF INFECTION AND PUBLIC HEALTH, 2022, 15 (06) : 670 - 676
  • [27] Cardiovascular Characteristics and Outcomes of Young Patients with COVID-19
    Trimaille, Antonin
    Ribeyrolles, Sophie
    Fauvel, Charles
    Chaumont, Corentin
    Weizman, Orianne
    Pommier, Thibaut
    Cellier, Joffrey
    Geneste, Laura
    Panagides, Vassili
    Marsou, Wassima
    Deney, Antoine
    Attou, Sabir
    Delmotte, Thomas
    Chemaly, Pascale
    Karsenty, Clement
    Giordano, Gauthier
    Gautier, Alexandre
    Guilleminot, Pierre
    Sagnard, Audrey
    Pastier, Julie
    Duceau, Baptiste
    Sutter, Willy
    Waldmann, Victor
    Pezel, Theo
    Mika, Delphine
    Cohen, Ariel
    Bonnet, Guillaume
    [J]. JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2021, 8 (12)
  • [28] Characteristics and Outcomes of Tracheostomized Patients With and Without COVID-19
    Bahk, Jeeyune
    Dolan, Bridget
    Sharma, Venus
    Sehmbhi, Mantej
    Fung, Jennifer Y.
    Lee, Young Im
    [J]. CRITICAL CARE EXPLORATIONS, 2023, 5 (08) : E0950
  • [29] Safety of Sotrovimab use in children with COVID-19: an Italian experience
    Venturini, Elisabetta
    Fusani, Lara
    Vecchio, Andrea Lo
    Scarano, Sara Maria
    Garazzino, Silvia
    Pruccoli, Giulia
    Dona, Daniele
    Lancella, Laura
    Gattinara, Guido Castelli
    Galli, Luisa
    [J]. JOURNAL OF CHEMOTHERAPY, 2024, 36 (01) : 45 - 48
  • [30] The clinical characteristics and risk factors for severe COVID-19 in patients with COVID-19 and tuberculosis coinfection
    Wang, Yang
    Chen, Yanping
    Gu, Lina
    Lou, Lixin
    Zhang, Jian
    Zhang, Kaiyu
    [J]. FRONTIERS IN MICROBIOLOGY, 2022, 13